Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia

Abstract

Aim: This post hoc analysis of a double-blind (DB), randomized, placebo-controlled, relapseprevention study evaluated the effects of paliperidone palmitate once-every-3-months (PP3M) in a subpopulation of adults with early illness schizophrenia (duration ≤5 years) from a clinical trial.Methods: Patients received either PP3M or placebo every 3 months in the DB phase. The primary efficacy variable was time from randomization to first relapse. Symptom severity, patient functioning, and safety were also assessed.Results: A total of 119 patients who entered the DB phase met the criteria for early illness schizophrenia (PP3M, n = 62; placebo, n = 57). PP3M significantly delayed time to relapse vs placebo (P = .035; hazard ratio, 3.08; 95% CI, 1.08-8.80). Symptomatic control and patient functioning were maintained in the PP3M group but significantly worsened in the placebo group.There were no unexpected tolerability findings.Conclusions: PP3M reduced relapse risk and maintained symptomatic and functional improvements compared with placebo in patients with early illness schizophrenia. K E Y W O R D Searly illness, paliperidone palmitate, recently diagnosed, relapse, schizophrenia

Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice

“…(Continued) confounding factor was that 14% of patients received antipsychotic polypharmacy, although many of these were prescribed low dose oral aripiprazole to treat hyperprolactinaemia. More formal RCTs found yearly relapse rates of 7%-9% (Bell Lynum et al, 2019;Berwaerts et al, 2015;Savitz et al, 2017). Our study findings are in agreement with other naturalistic studies (Garcia-Portilla et al, 2020) that PP3M is highly effective at preventing relapse.…”

Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review

“…Another similar study conducted demonstrated that among the different formulations offered for palmitate paliperidone, including the 3-month formulation and 1-month formulation, the 3-month formulation was better at preventing relapse in schizophrenic patients ( 44 ). Furthermore, another study conducted to compare the prevention in relapse in schizophrenic patients offered palmitate paliperidone 3-month formulation compared to placebo treatment showed that palmitate paliperidone 3-month formulation was better at preventing relapse ( 46 ). Moreover, schizophrenic patients who had been administered PP3M had fewer reported hospitalizations for psychiatric and social reasons as compared to patients who were given placebo ( 47 ).…”